Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Published . Updated .
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Directly affected
- LLY Eli Lilly
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Source: CNBC Top
How far Eli Lilly (LLY) has moved since 30 Sep 2026
Since the first closing price after “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” Eli Lilly (LLY) is +7.85%. The S&P 500 fund (SPY) is +0.33% over the same days, a +7.52% difference versus the market.
Filings that name Eli Lilly (LLY) around 30 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 1 days before publication, inside 30 days. The filing is listed beside the story “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 19 days before publication, inside 30 days. The filing is listed beside the story “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.”
- Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 26 days before publication, inside 30 days. The filing is listed beside the story “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 58 days before publication, inside 60 days. The filing is listed beside the story “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Where this story sits: Taiwan Strait
Taiwan Strait has 49 linked stories in the last 7 days and 49 in the last 30 on the page that also carries “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.” The recent pace is rising.
Who gains and who loses around Eli Lilly (LLY)
Companies carried with this story
- LLY Eli Lilly
For “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” Eli Lilly (LLY) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ELI LILLY & CO in the headline; GA resolved that company to LLY
- ACHC Acadia Healthcare
In “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
What Taiwan Strait means for Eli Lilly (LLY)
Eli Lilly (LLY) is the company in “Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial,” the 30 Sep 2026 Taiwan Strait story.
For Eli Lilly (LLY), the reason on file says The reported development directly names ELI LILLY & CO in the headline; GA resolved that company to LLY
Acadia Healthcare (ACHC) is here too. Its reason reads: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Eli Lilly (LLY)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65.
How strong the case is around Eli Lilly (LLY)
46 out of 100
“Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.